Description

R-(+)-Atenolol

R-(+)-Atenolol is the pharmacologically active enantiomer of Atenolol, a selective β1-adrenergic receptor blocker used in oral formulations for the treatment of hypertension, angina pectoris, and certain arrhythmias. As a stereochemically pure beta-blocker, R-(+)-Atenolol offers a more targeted cardiovascular effect profile with reduced β2-related side effects compared to its racemic counterpart. R-(+)-Atenolol

• Is a high-purity, single-enantiomer beta-1 selective adrenergic antagonist
• Provides cardioselective activity with minimized off-target β2 effects
• Is suitable for oral solid dosage forms (e.g., tablets, capsules)

Atenolol belongs to the class of cardioselective β1-adrenergic blockers. While conventional formulations use the racemic mixture (R,S-Atenolol), research indicates that the R-(+) enantiomer is primarily responsible for the therapeutic β1 blockade, while the S-(−) enantiomer contributes minimally or not at all to the clinical effect. By isolating the R-(+) form, formulations can offer effective antihypertensive and antianginal activity with improved tolerability and fewer β2-related side effects such as bronchoconstriction.

In pharmaceutical development, R-(+)-Atenolol is used in:

• Monotherapy for hypertension, reducing systolic and diastolic blood pressure via selective β1 blockade
• Chronic management of angina pectoris, lowering myocardial oxygen demand
• Adjunctive therapy in arrhythmias, particularly for rate control in supraventricular tachyarrhythmias
• Investigational chiral switch formulations, where pure enantiomers replace racemates to enhance safety or efficacy

Formulators using R-(+)-Atenolol benefit from improved stereoselective dosing, which may allow lower total drug loads and more precise pharmacokinetics in development programs focused on chiral optimization.

CarboMer supplies R-(+)-Atenolol with validated chiral purity (typically >99%) and tight control over enantiomeric excess, residual solvents, and related substances. The API is suitable for stereospecific drug product development under global regulatory frameworks.

The material is packaged in sealed, tamper-evident, moisture-protected containers. Available in both R&D and commercial-scale quantities. Minimum order quantities (MOQ), lead times, and complete technical documentation are available upon request.

Each batch is tested for optical rotation, assay, related substances, chiral purity (e.g., HPLC or CE), residual solvents, and microbial limits in line with pharmacopeial expectations.

As with all CarboMer APIs, R-(+)-Atenolol is supported by technical consultation, regulatory assistance, and lifecycle documentation services helping innovators bring stereochemically optimized cardiovascular therapies to global markets.